A second Remicade biosimilar hit the U.S. market to take a larger slash at pricing.
After an average 44% price cuts, Chinese government will add some blockbuster foreign meds like Celgene's Revlimid to its national insurance scheme.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
With a patent loss looming, Takeda filed a citizen petition pushing the FDA to knock back generic Velcade competition.
The European Medicines Agency today recommended approval of Imraldi, a Humira biosimilar from Samsung and Biogen.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Dr. Reddy’s is recalling 765,058 cartons of its Zenatane acne med, which was manufactured for it by compatriot Cipla.
Lingering regulatory problems at the Sun Pharma plant Halol, India, have contributed to a $14.1 billion slide in founder Dilip Shanghvi’s net worth.…
Takeda’s cancer unit debuted a new face at this year’s ASCO—and the company was quick to bill it as such.
Nonprofit executive Ethan Brewster can suddenly create body doubles of himself. If it sounds like a Marvel superhero comic plot, that’s because it is.
GSK's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead.
Dead set on defending its top drug, Johnson & Johnson is taking South Korea’s Samsung Bioepis to federal court over a biosim launch.